Globus Medical, Inc. (NYSE: GMED) Stock Competitors & Peer Comparison

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ABT has a market cap of 188.2B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ABT trades at $108.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ABT's P/E ratio is 20.88. In terms of profitability, GMED's ROE is +0.12%, compared to ABT's ROE of +0.11%. Regarding short-term risk, GMED is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for GMED.Check ABT's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, GMED's ROE is +0.12%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, GMED is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for GMED.Check BSX-PA's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, MDT has a market cap of 119.2B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while MDT trades at $94.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas MDT's P/E ratio is 16.84. In terms of profitability, GMED's ROE is +0.12%, compared to MDT's ROE of +0.14%. Regarding short-term risk, GMED is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for GMED.Check MDT's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SYK has a market cap of 118.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SYK trades at $304.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SYK's P/E ratio is 23.00. In terms of profitability, GMED's ROE is +0.12%, compared to SYK's ROE of +0.16%. Regarding short-term risk, GMED is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for GMED.Check SYK's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BSX has a market cap of 69.8B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BSX trades at $48.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BSX's P/E ratio is 15.15. In terms of profitability, GMED's ROE is +0.12%, compared to BSX's ROE of +0.15%. Regarding short-term risk, GMED is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for GMED.Check BSX's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while EW trades at $90.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas EW's P/E ratio is 33.25. In terms of profitability, GMED's ROE is +0.12%, compared to EW's ROE of +0.10%. Regarding short-term risk, GMED is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for GMED.Check EW's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, DXCM has a market cap of 33.9B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while DXCM trades at $88.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas DXCM's P/E ratio is 35.18. In terms of profitability, GMED's ROE is +0.12%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, GMED is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for GMED.Check DXCM's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, GEHC has a market cap of 31.5B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while GEHC trades at $68.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas GEHC's P/E ratio is 15.29. In terms of profitability, GMED's ROE is +0.12%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, GMED is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for GMED.Check GEHC's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, PHG has a market cap of 25.5B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while PHG trades at $25.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas PHG's P/E ratio is 14.88. In terms of profitability, GMED's ROE is +0.12%, compared to PHG's ROE of +0.10%. Regarding short-term risk, GMED is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for GMED.Check PHG's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ZBH has a market cap of 19.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ZBH trades at $98.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ZBH's P/E ratio is 11.67. In terms of profitability, GMED's ROE is +0.12%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, GMED is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for GMED.Check ZBH's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ABMD's P/E ratio is 65.36. In terms of profitability, GMED's ROE is +0.12%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, GMED is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for GMED.Check ABMD's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while PEN trades at $322.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas PEN's P/E ratio is 83.90. In terms of profitability, GMED's ROE is +0.12%, compared to PEN's ROE of +0.11%. Regarding short-term risk, GMED is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for GMED.Check PEN's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SWAV's P/E ratio is 78.76. In terms of profitability, GMED's ROE is +0.12%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, GMED is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for GMED.Check SWAV's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SNN trades at $28.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SNN's P/E ratio is 13.50. In terms of profitability, GMED's ROE is +0.12%, compared to SNN's ROE of +0.12%. Regarding short-term risk, GMED is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for GMED.Check SNN's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ALGN trades at $158.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ALGN's P/E ratio is 14.57. In terms of profitability, GMED's ROE is +0.12%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, GMED is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for GMED.Check ALGN's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while GKOS trades at $178.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas GKOS's P/E ratio is -209.80. In terms of profitability, GMED's ROE is +0.12%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, GMED is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for GMED.Check GKOS's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BIO trades at $385.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BIO's P/E ratio is 41.79. In terms of profitability, GMED's ROE is +0.12%, compared to BIO's ROE of +0.03%. Regarding short-term risk, GMED is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for GMED.Check BIO's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BIO-B trades at $381.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BIO-B's P/E ratio is -67.15. In terms of profitability, GMED's ROE is +0.12%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, GMED is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for GMED.Check BIO-B's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, PODD has a market cap of 10.4B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while PODD trades at $146.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas PODD's P/E ratio is 25.65. In terms of profitability, GMED's ROE is +0.12%, compared to PODD's ROE of +0.27%. Regarding short-term risk, GMED is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for GMED.Check PODD's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas MASI's P/E ratio is 44.43. In terms of profitability, GMED's ROE is +0.12%, compared to MASI's ROE of +0.09%. Regarding short-term risk, GMED is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for GMED.Check MASI's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BRKR has a market cap of 9B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BRKR trades at $58.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BRKR's P/E ratio is 29.85. In terms of profitability, GMED's ROE is +0.12%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, GMED is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for GMED.Check BRKR's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BRKRP trades at $432.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BRKRP's P/E ratio is 238.04. In terms of profitability, GMED's ROE is +0.12%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, GMED is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for GMED.Check BRKRP's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas NARI's P/E ratio is -59.24. In terms of profitability, GMED's ROE is +0.12%, compared to NARI's ROE of -0.00%. Regarding short-term risk, GMED is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for GMED.Check NARI's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while HAE trades at $103.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas HAE's P/E ratio is 20.52. In terms of profitability, GMED's ROE is +0.12%, compared to HAE's ROE of +0.11%. Regarding short-term risk, GMED is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for GMED.Check HAE's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while LIVN trades at $82.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas LIVN's P/E ratio is 19.29. In terms of profitability, GMED's ROE is +0.12%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, GMED is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for GMED.Check LIVN's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ITGR trades at $126.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ITGR's P/E ratio is 19.76. In terms of profitability, GMED's ROE is +0.12%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, GMED is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for GMED.Check ITGR's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while IRTC trades at $122.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas IRTC's P/E ratio is -287.05. In terms of profitability, GMED's ROE is +0.12%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, GMED is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for GMED.Check IRTC's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas AXNX's P/E ratio is -709.80. In terms of profitability, GMED's ROE is +0.12%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, GMED is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for GMED.Check AXNX's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while TMDX trades at $88.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas TMDX's P/E ratio is 44.15. In terms of profitability, GMED's ROE is +0.12%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, GMED is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for GMED.Check TMDX's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while NEOG trades at $11.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas NEOG's P/E ratio is 41.57. In terms of profitability, GMED's ROE is +0.12%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, GMED is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for GMED.Check NEOG's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while AXGN trades at $48.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas AXGN's P/E ratio is 123.95. In terms of profitability, GMED's ROE is +0.12%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, GMED is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for GMED.Check AXGN's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while UFPT trades at $287.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas UFPT's P/E ratio is 29.27. In terms of profitability, GMED's ROE is +0.12%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, GMED is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for GMED.Check UFPT's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ESTA trades at $74.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ESTA's P/E ratio is -57.38. In terms of profitability, GMED's ROE is +0.12%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, GMED is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for GMED.Check ESTA's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas NUVA's P/E ratio is 75.00. In terms of profitability, GMED's ROE is +0.12%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, GMED is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for GMED.Check NUVA's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while NVCR trades at $17.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas NVCR's P/E ratio is -13.57. In terms of profitability, GMED's ROE is +0.12%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, GMED is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for GMED.Check NVCR's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BFLY trades at $7.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BFLY's P/E ratio is -30.35. In terms of profitability, GMED's ROE is +0.12%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, GMED is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for GMED.Check BFLY's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while INSP trades at $63.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas INSP's P/E ratio is 27.34. In terms of profitability, GMED's ROE is +0.12%, compared to INSP's ROE of +0.18%. Regarding short-term risk, GMED is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for GMED.Check INSP's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while CNMD trades at $49.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas CNMD's P/E ratio is 10.84. In terms of profitability, GMED's ROE is +0.12%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, GMED is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for GMED.Check CNMD's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ATEC trades at $9.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ATEC's P/E ratio is -155.50. In terms of profitability, GMED's ROE is +0.12%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, GMED is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for GMED.Check ATEC's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while TNDM trades at $20.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas TNDM's P/E ratio is -21.97. In terms of profitability, GMED's ROE is +0.12%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, GMED is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for GMED.Check TNDM's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas HSKA's P/E ratio is -62.49. In terms of profitability, GMED's ROE is +0.12%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, GMED is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for GMED.Check HSKA's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while IART trades at $16.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas IART's P/E ratio is 6.97. In terms of profitability, GMED's ROE is +0.12%, compared to IART's ROE of -0.01%. Regarding short-term risk, GMED is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for GMED.Check IART's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while AORT trades at $25.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas AORT's P/E ratio is 42.67. In terms of profitability, GMED's ROE is +0.12%, compared to AORT's ROE of -0.01%. Regarding short-term risk, GMED is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for GMED.Check AORT's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while PRCT trades at $22.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas PRCT's P/E ratio is -11.02. In terms of profitability, GMED's ROE is +0.12%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, GMED is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for GMED.Check PRCT's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas AVNS's P/E ratio is 27.77. In terms of profitability, GMED's ROE is +0.12%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, GMED is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for GMED.Check AVNS's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while LMRI trades at $12.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas LMRI's P/E ratio is -23.15. In terms of profitability, GMED's ROE is +0.12%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, GMED is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for GMED.Check LMRI's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SILK's P/E ratio is -18.96. In terms of profitability, GMED's ROE is +0.12%, compared to SILK's ROE of -0.35%. Regarding short-term risk, GMED is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for GMED.Check SILK's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ENOV trades at $18.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ENOV's P/E ratio is 5.55. In terms of profitability, GMED's ROE is +0.12%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, GMED is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for GMED.Check ENOV's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while IRMD trades at $84.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas IRMD's P/E ratio is 43.51. In terms of profitability, GMED's ROE is +0.12%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, GMED is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for GMED.Check IRMD's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas FNA's P/E ratio is -19.83. In terms of profitability, GMED's ROE is +0.12%, compared to FNA's ROE of -0.35%. Regarding short-term risk, GMED is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for GMED.Check FNA's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BVS has a market cap of 972.9M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BVS trades at $14.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BVS's P/E ratio is 18.89. In terms of profitability, GMED's ROE is +0.12%, compared to BVS's ROE of +0.28%. Regarding short-term risk, GMED is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for GMED.Check BVS's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, CBLL has a market cap of 932.3M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while CBLL trades at $24.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas CBLL's P/E ratio is -13.96. In terms of profitability, GMED's ROE is +0.12%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, GMED is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for GMED.Check CBLL's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BBNX has a market cap of 896.2M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BBNX trades at $19.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BBNX's P/E ratio is -12.07. In terms of profitability, GMED's ROE is +0.12%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, GMED is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for GMED.Check BBNX's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, AHCO has a market cap of 873.5M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while AHCO trades at $6.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas AHCO's P/E ratio is 13.10. In terms of profitability, GMED's ROE is +0.12%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, GMED is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for GMED.Check AHCO's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, INMD has a market cap of 853M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while INMD trades at $14.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas INMD's P/E ratio is 10.31. In terms of profitability, GMED's ROE is +0.12%, compared to INMD's ROE of +0.12%. Regarding short-term risk, GMED is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for GMED.Check INMD's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, AVR has a market cap of 847.9M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while AVR trades at $9.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas AVR's P/E ratio is -4.49. In terms of profitability, GMED's ROE is +0.12%, compared to AVR's ROE of -0.78%. Regarding short-term risk, GMED is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for GMED.Check AVR's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas CSII's P/E ratio is -20.83. In terms of profitability, GMED's ROE is +0.12%, compared to CSII's ROE of -0.14%. Regarding short-term risk, GMED is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for GMED.Check CSII's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SIBN has a market cap of 826.7M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SIBN trades at $18.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SIBN's P/E ratio is -54.82. In terms of profitability, GMED's ROE is +0.12%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, GMED is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for GMED.Check SIBN's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, VREX has a market cap of 779.7M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while VREX trades at $18.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas VREX's P/E ratio is 19.49. In terms of profitability, GMED's ROE is +0.12%, compared to VREX's ROE of +0.05%. Regarding short-term risk, GMED is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for GMED.Check VREX's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SSII has a market cap of 678.4M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SSII trades at $3.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SSII's P/E ratio is -66.12. In terms of profitability, GMED's ROE is +0.12%, compared to SSII's ROE of -0.27%. Regarding short-term risk, GMED is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for GMED.Check SSII's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SRDX's P/E ratio is -34.66. In terms of profitability, GMED's ROE is +0.12%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, GMED is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for GMED.Check SRDX's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, CTKB has a market cap of 607M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while CTKB trades at $4.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas CTKB's P/E ratio is -24.90. In terms of profitability, GMED's ROE is +0.12%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, GMED is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for GMED.Check CTKB's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, KIDS has a market cap of 580.2M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while KIDS trades at $22.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas KIDS's P/E ratio is -19.14. In terms of profitability, GMED's ROE is +0.12%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, GMED is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for GMED.Check KIDS's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas APEN's P/E ratio is -9.43. In terms of profitability, GMED's ROE is +0.12%, compared to APEN's ROE of -0.85%. Regarding short-term risk, GMED is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for GMED.Check APEN's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, DCTH has a market cap of 568.9M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while DCTH trades at $16.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas DCTH's P/E ratio is 1648.00. In terms of profitability, GMED's ROE is +0.12%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, GMED is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for GMED.Check DCTH's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, GMED's ROE is +0.12%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, GMED is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for GMED.Check ZIMV's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, CERS has a market cap of 517.9M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while CERS trades at $2.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas CERS's P/E ratio is -51.30. In terms of profitability, GMED's ROE is +0.12%, compared to CERS's ROE of -0.10%. Regarding short-term risk, GMED is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for GMED.Check CERS's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, NPCE has a market cap of 502.9M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while NPCE trades at $14.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas NPCE's P/E ratio is -25.88. In terms of profitability, GMED's ROE is +0.12%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, GMED is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for GMED.Check NPCE's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, TCMD has a market cap of 496.5M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while TCMD trades at $21.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas TCMD's P/E ratio is 20.38. In terms of profitability, GMED's ROE is +0.12%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, GMED is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for GMED.Check TCMD's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SGHT has a market cap of 456M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SGHT trades at $8.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SGHT's P/E ratio is -14.96. In terms of profitability, GMED's ROE is +0.12%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, GMED is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for GMED.Check SGHT's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, CARL has a market cap of 421.9M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while CARL trades at $15.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas CARL's P/E ratio is -10.85. In terms of profitability, GMED's ROE is +0.12%, compared to CARL's ROE of -0.38%. Regarding short-term risk, GMED is less volatile compared to CARL. This indicates lower risk in terms of short-term price fluctuations for GMED.Check CARL's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, CLPT has a market cap of 421.4M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while CLPT trades at $14.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas CLPT's P/E ratio is -11.91. In terms of profitability, GMED's ROE is +0.12%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, GMED is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for GMED.Check CLPT's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SENS has a market cap of 413.8M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SENS trades at $9.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SENS's P/E ratio is -4.44. In terms of profitability, GMED's ROE is +0.12%, compared to SENS's ROE of -1.66%. Regarding short-term risk, GMED is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for GMED.Check SENS's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, PACB has a market cap of 403.8M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while PACB trades at $1.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas PACB's P/E ratio is -3.17. In terms of profitability, GMED's ROE is +0.12%, compared to PACB's ROE of -49.62%. Regarding short-term risk, GMED is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for GMED.Check PACB's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, OFIX has a market cap of 376.3M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while OFIX trades at $9.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas OFIX's P/E ratio is -6.06. In terms of profitability, GMED's ROE is +0.12%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, GMED is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for GMED.Check OFIX's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, CATX has a market cap of 354.7M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while CATX trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas CATX's P/E ratio is -2.34. In terms of profitability, GMED's ROE is +0.12%, compared to CATX's ROE of -0.42%. Regarding short-term risk, GMED is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for GMED.Check CATX's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, TMCI has a market cap of 316.6M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while TMCI trades at $4.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas TMCI's P/E ratio is -5.19. In terms of profitability, GMED's ROE is +0.12%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, GMED is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for GMED.Check TMCI's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas SMLR's P/E ratio is 3.92. In terms of profitability, GMED's ROE is +0.12%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, GMED is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for GMED.Check SMLR's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, TLSI has a market cap of 306.6M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while TLSI trades at $5.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas TLSI's P/E ratio is -2.96. In terms of profitability, GMED's ROE is +0.12%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, GMED is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for GMED.Check TLSI's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, CV has a market cap of 298.3M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while CV trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas CV's P/E ratio is -2.39. In terms of profitability, GMED's ROE is +0.12%, compared to CV's ROE of -1.78%. Regarding short-term risk, GMED is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for GMED.Check CV's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, RCEL has a market cap of 271.8M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while RCEL trades at $11.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas RCEL's P/E ratio is -7.60. In terms of profitability, GMED's ROE is +0.12%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, GMED is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for GMED.Check RCEL's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, RXST has a market cap of 270.7M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while RXST trades at $6.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas RXST's P/E ratio is -5.79. In terms of profitability, GMED's ROE is +0.12%, compared to RXST's ROE of -0.17%. Regarding short-term risk, GMED is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for GMED.Check RXST's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, PROF has a market cap of 247.1M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while PROF trades at $6.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas PROF's P/E ratio is -6.94. In terms of profitability, GMED's ROE is +0.12%, compared to PROF's ROE of -0.56%. Regarding short-term risk, GMED is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for GMED.Check PROF's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, INFU has a market cap of 245.4M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while INFU trades at $12.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas INFU's P/E ratio is 29.66. In terms of profitability, GMED's ROE is +0.12%, compared to INFU's ROE of +0.15%. Regarding short-term risk, GMED is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for GMED.Check INFU's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas MGRM's P/E ratio is -12.00. In terms of profitability, GMED's ROE is +0.12%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, GMED is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for GMED.Check MGRM's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ELMD has a market cap of 228.4M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ELMD trades at $27.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ELMD's P/E ratio is 21.06. In terms of profitability, GMED's ROE is +0.12%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, GMED is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for GMED.Check ELMD's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas NVRO's P/E ratio is -1.91. In terms of profitability, GMED's ROE is +0.12%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, GMED is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for GMED.Check NVRO's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas BSGM's P/E ratio is -5.81. In terms of profitability, GMED's ROE is +0.12%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, GMED is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for GMED.Check BSGM's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, STIM has a market cap of 189.3M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while STIM trades at $2.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas STIM's P/E ratio is -6.18. In terms of profitability, GMED's ROE is +0.12%, compared to STIM's ROE of -1.51%. Regarding short-term risk, GMED is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for GMED.Check STIM's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, LUCD has a market cap of 181.5M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while LUCD trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas LUCD's P/E ratio is -2.57. In terms of profitability, GMED's ROE is +0.12%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, GMED is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for GMED.Check LUCD's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas MDGS's P/E ratio is -0.27. In terms of profitability, GMED's ROE is +0.12%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, GMED is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for GMED.Check MDGS's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas QIPT's P/E ratio is -15.87. In terms of profitability, GMED's ROE is +0.12%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, GMED is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for GMED.Check QIPT's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, FOCL has a market cap of 156.3M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while FOCL trades at $4.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas FOCL's P/E ratio is -4.03. In terms of profitability, GMED's ROE is +0.12%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, GMED is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for GMED.Check FOCL's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, QSI has a market cap of 153.1M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while QSI trades at $0.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas QSI's P/E ratio is -1.68. In terms of profitability, GMED's ROE is +0.12%, compared to QSI's ROE of -0.47%. Regarding short-term risk, GMED is more volatile compared to QSI. This indicates higher risk in terms of short-term price fluctuations for GMED.Check QSI's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, INGN has a market cap of 147.6M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while INGN trades at $5.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas INGN's P/E ratio is -5.99. In terms of profitability, GMED's ROE is +0.12%, compared to INGN's ROE of -0.13%. Regarding short-term risk, GMED is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for GMED.Check INGN's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, QTRX has a market cap of 121.5M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while QTRX trades at $2.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas QTRX's P/E ratio is -1.02. In terms of profitability, GMED's ROE is +0.12%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, GMED is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for GMED.Check QTRX's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas ICAD's P/E ratio is -20.37. In terms of profitability, GMED's ROE is +0.12%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, GMED is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for GMED.Check ICAD's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, LNSR has a market cap of 101.3M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while LNSR trades at $8.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas LNSR's P/E ratio is 8.42. In terms of profitability, GMED's ROE is +0.12%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, GMED is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for GMED.Check LNSR's competition here

Globus Medical, Inc. (NYSE: GMED) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GMED stands at 10.5B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, GMED is priced at $78.64 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GMED currently has a P/E ratio of 17.59, whereas HJLI's P/E ratio is N/A. In terms of profitability, GMED's ROE is +0.12%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, GMED is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for GMED.Check HJLI's competition here